1. Home
  2. REI vs AKBA Comparison

REI vs AKBA Comparison

Compare REI & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ring Energy Inc.

REI

Ring Energy Inc.

HOLD

Current Price

$1.40

Market Cap

354.3M

Sector

Energy

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.86

Market Cap

343.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REI
AKBA
Founded
2004
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
354.3M
343.4M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
REI
AKBA
Price
$1.40
$0.86
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.67
AVG Volume (30 Days)
3.4M
3.9M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
$307,178,072.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$0.82
52 Week High
$2.00
$3.32

Technical Indicators

Market Signals
Indicator
REI
AKBA
Relative Strength Index (RSI) 63.76 28.44
Support Level $1.23 N/A
Resistance Level $1.42 $1.54
Average True Range (ATR) 0.06 0.07
MACD 0.01 -0.04
Stochastic Oscillator 93.18 2.95

Price Performance

Historical Comparison
REI
AKBA

About REI Ring Energy Inc.

Ring Energy Inc is an independent oil and natural gas exploration and production company based in the United States. It is engaged in oil and natural gas development, production, acquisition, and exploration activities, currently focused on the Permian Basin of Texas. The company's drilling operations target the oil and liquids-rich producing formations in the Northwest Shelf and the Central Basin Platform, in the Permian Basin in Texas.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: